Abstract
In this chapter we discuss operational challenges that are specific to adaptive trials (as well as complex nonadaptive trials): essentially, the need to validate the design, to control the trial centrally, to collect and analyze key data rapidly, to preserve the trial blinding and integrity, and to document all important adaptive decisions taken. We illustrate these challenges using an actual phase I trial in oncology, and argue that the issues can be addressed through proper planning, choice of experienced vendors and independent groups (coordinating center and DSMB), statistical teams with adequate expertise in the design chosen (randomization and CRM), recourse to efficient computer technology (IWRS, EDC, automated e-mailing), and oversight by a team that must be as flexible as the trial design!
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chow SC, Chang M (2008) Adaptive design methods in clinical trials – a review. Orphanet J Rare Dis 3:11
DeMets DL, Furberg CD, Friedman LM (eds) (2006) Data monitoring in clinical trials: a case studies approach. Springer, New York. ISBN 0-387-20330-3
Ellenberg SE, Fleming TR, DeMets DL (2002) Data monitoring committees in clinical trials: a practical perspective. Wiley, Chichester. ISBN 0-471-48986-7
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): guideline on data monitoring committees. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf (July 2005). Accessed 30 Sep 2013
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf (October 2007). Accessed 30 Sep 2013
European Medicines Agency. Reflection paper on risk based quality management in clinical trials. EMA/INS/GCP/394194/2011.  http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500110059.pdf (February 2011). Accessed 30 Sep 2013
Fardipour P, Littman G, Burns DD et al (2009a) Planning and executing response-adaptive learn-phase clinical trials: 1. The process. Drug Inf J 43:713–724
Fardipour P, Littman G, Burns DD et al (2009b) Planning and executing response-adaptive learn-phase clinical trials: 2. Case studies. Drug Inf J 43:725–734
Food and Drug Administration (FDA) (2006) guidance for industry – establishment and operation of clinical trial data monitoring committees. http://www.fda.gov/downloads/Regulatoryinformation/Guidances/ucm127073.pdf. Accessed 30 Sep 2013
Food and Drug Administration (FDA) (2010) Guidance for clinical trial sponsors – adaptive design clinical trials for drugs and biologics. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm201790.pdf. Accessed 30 Sep 2013
Food and Drug Administration (FDA) (2013) Guidance for industry: oversight of clinical investigations –a risk-based approach to monitoring. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf. Accessed 30 Sep2013
Gallo P (2006) Confidentiality and trial integrity issues for adaptive designs. Drug Inf J 40:445–450
Gallo P, Chuang-Stein C, Dragalin V et al (2006) Adaptive designs in clinical drug development – an executive summary of the PhRMA Working Group. J Biopharm Stat 16:275–283
Gaydos B, Anderson KM, Berry D et al (2009) Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J 43:539–556
Herson J (2009) Data and safety monitoring committees in clinical trials. Chapman & Hall, Boca Raton, FL. ISBN 978-1-4200-7037-8
Krams M, Burman CF, Dragalin V et al (2007) Adaptive designs in clinical drug development: opportunities, challenges, and scope. Reflections following PhRMA's November 2006 workshop. J Biopharm Stat 17:957–964
Maca J, Bhattacharya S, Dragalin V et al (2006) Adaptive seamless phase II/III designs – background, operational aspects, and examples. Drug Inf J 40:463–473
O’Quigley J, Shen LZ (1996) Continual reassessment method: a likelihood approach. Biometrics 52:673–684
Paoletti X, Baron B, Schöffski P et al (2006) Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study. Eur J Cancer 42:1362–1368
Quinlan JA, Krams M (2006) Implementing adaptive designs: logistical and operational considerations. Drug Inf J 40:437–444
Quinlan J, Gaydos B, Maca J, Krams M (2010) Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials 7:167–173
Shen J, Preskorn S, Dragalin V et al (2011) How adaptive designs can increase efficiency in psychiatric drug development: a case study. Innov Clin Neurosci 8:26–34
Storer BE (2001) An evaluation of phase I clinical trial designs in the continuous dose–response setting. Stat Med 20:2399–2408
Acknowledgments
The authors are grateful to Dr. Vlad Dragalin for suggesting useful references, and to the book editors for their careful review of this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Danielson, L., Carlier, J., Burzykowski, T., Buyse, M. (2014). Implementation Issues in Adaptive Design Trials. In: He, W., Pinheiro, J., Kuznetsova, O. (eds) Practical Considerations for Adaptive Trial Design and Implementation. Statistics for Biology and Health. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1100-4_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1100-4_12
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1099-1
Online ISBN: 978-1-4939-1100-4
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)